Prognostic factors and adjuvant therapy in uterine carcinosarcoma

European Journal of Gynaecological Oncology

Volumn 29, Issue 5, 2008, Pages 483-488

  Wu, T I ^a   Hsu, K H ^a   Huang, H J ^a   Hsueh, S ^a   Chou, H H ^a   Tsai, C S ^a   Ho, K C ^a   Chao, A ^a   Chang, T C ^a   Lai, C H ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Chemoradiation; Chemotherapy; Malignant mixed m llerian tumor; Prognostic factor; Uterine carcinosarcoma

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; APPENDECTOMY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MYOMETRIUM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SURVIVAL TIME; TREND STUDY; UTERINE CARCINOSARCOMA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; UTERINE NEOPLASMS;

EID: 54949140459     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Brooks S.E., Zhan M., Cote T., Baquet C.R.: "Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989-1999". Gynecol. Oncol., 2004, 93, 204.
2. Nordal R.R., Thoresen S.Ø.: "Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality". Eur. J. Cancer, 1996, 33, 907.
3. McCluggage W.G..: "Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?". J. Clin. Pathol., 2002, 55, 321.
4. Silverberg S.G., Major F.J., Blessing J.A., Fetter B., Askin F.B., Liao S.Y. et al.: "Carcinosarcoma (MMMT) of the uterus: a GOG pathologic study of 203 cases". Int. J. Gynecol. Pathol., 1990, 9, 1.
5. Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman W.T., Currie J.L. et al.: "Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study". Cancer, 1993, 71 (suppl.), 1702.
6. Iwasa Y., Haga H., Konishi I., Kobashi Y., Higuchi K., Katsuyama E. et al.: "Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients". Cancer, 1998, 82, 512.
7. Yamada D.S., Burger R.A., Brewster W.R., Anton D., Kohler M.F., Monk B.J.: "Prognostic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus ". Cancer, 2000, 88, 2782.
8. Sartori E., Bazzurini L., Gadducci A., Landoni F., Lissoni A., Maggino T. et al.: "Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study". Gynecol. Oncol., 1997, 67, 70.
9. Amant F., Cadron I., Fuso L., Berteloot P., Jonge E., Jacomen G. et al.: "Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk endothelial endometrial cancer". Gynecol. Oncol., 2005, 98, 274.
10. Kanjeekal S., Chambers A., Fung M.F.K., Verma S.: "Systemic therapy for advanced uterine sarcoma: a systematic review of the literature". Gynecol. Oncol., 2005, 97, 624.
11. McCluggage W.G., Haller U., Kurman R.J.: "Mixed epithelial and mesenchymal tumours ". In: Tavassoli F.A., Decilee P. (eds.). World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, 2003, 245.
12. SPSS for windows, Rel 11.0.1. Chicago, SPSS. Inc., 2001.
13. SAS Statistical Package, Version 8.1. Cary, NC: SAS Institute, Inc., 2000.
14. Gerszten K., Faul C., Kounelis S., Huang Q., Kelly J., Jones M.W.: "The impact of adjuvant radiotherapy on carcinosarcoma of the uterus". Gynecol. Oncol., 1998, 68, 8.
15. Callister M., Ramondetta L.M., Jhingran A., Burke T.W., Eifel P.J.: "Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome". Int. J. Radiat. Oncol. Biol. Phy., 2004, 58, 786.
16. Manolitsas T.P., Wain G.V., Willians K.E., Freidlander M., Hacker N.F.: "Multimodality therapy for patients with clinical Stage I and II malignant mixed müllerian tumors of the uterus". Cancer, 2001, 91, 1437.
17. Menczer J., Levy T., Piura B., Chetrit A., Altaras M., Meirovitz M. et al.: "A comparison between different postoperative treatment modalities of uterine carcinosarcoma". Gynecol. Oncol., 2005, 97, 166.
18. Sutton G., Kauderer J., Carson L.F., Lentz S.S., Whitney C.W., Gallion H.: "Adjuvant ifosfamide and cisplatin in patients with completely resected Stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncologic Group study". Gynecol. Oncol., 2005, 96, 630.
19. Wolfson A.H., Brady M.F., Mannel R.S., Lee Y., Futoran R.J., Cohn D. et al.: "A Gynecologic Oncology Group randomized trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide+mesna (CIM) in optimally debulked Stage I-IV carcinosarcoma (CS) of the uterus". Gynecol. Oncol., 2007, 107, 166.
20. Omura G.A., Major F.J., Blessing J.A., Sedlacek T.V., Thigpen J.T., Creasman W.T. et al.: "A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas". Cancer, 1983, 52, 626.
21. Sutton G., Brunetto V.L., Kilgore L., Soper J.T., McGehee R., Olt G. et al.: "A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group study". Gynecol. Oncol., 2000, 79, 147.
22. Homesley H.D., Filiaci V., Markman M., Bitterman P., Eaton L., Kilgore L.C. et al.: "Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study". J. Clin. Oncol., 2007, 25, 526.
23. Miller D.S., Blessing J.A., Schilder J., Munkarah A., Lee Y.C.: "Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study". Gynecol. Oncol., 2005, 98, 217.
24. Carmen M.G., Fuller A.F., Matulonis U., Horick N.K., Goodman A., Duska L.R. et al.: "Phase II trial of anastrozole in women with asymptomatic müllerian cancer". Gynecol. Oncol., 2003, 91, 596.
25. Kuo D.Y.S., Timmins P., Blank S.V., Fields A.L., Goldberg G.L., Murgo A. et al.: "Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York phase II consortium". Gynecol. Oncol., 2006, 100, 160.